Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$2.18
-0.9%
$2.38
$2.00
$5.20
$234.12M1.28616,813 shs444,799 shs
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$0.09
-44.6%
$0.12
$0.09
$2.48
$2.45M0.942.28 million shs14.57 million shs
Relx Nv stock logo
RENX
Relx
$21.19
$0.00
$20.06
$23.30
N/AN/A100,590 shs547,934 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MaxCyte, Inc. stock logo
MXCT
MaxCyte
0.00%+7.84%-4.35%-19.41%-43.88%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00%0.00%0.00%+9,409,900.00%+9,409,900.00%
Relx Nv stock logo
RENX
Relx
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MaxCyte, Inc. stock logo
MXCT
MaxCyte
2.7531 of 5 stars
3.53.00.00.02.51.70.6
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Relx Nv stock logo
RENX
Relx
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.00
Buy$7.50244.04% Upside
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00
N/AN/AN/A
Relx Nv stock logo
RENX
Relx
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$38.63M6.01N/AN/A$1.95 per share1.12
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$350K6.99N/AN/AN/A
Relx Nv stock logo
RENX
Relx
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$41.06M-$0.40N/AN/AN/A-110.92%-19.90%-17.24%8/5/2025 (Estimated)
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/A-$1.55N/AN/AN/AN/AN/AN/A
Relx Nv stock logo
RENX
Relx
N/A$1.2217.37N/AN/AN/AN/AN/A

Latest PTN, YGEN, MXCT, OSL, and RENX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
Relx Nv stock logo
RENX
Relx
$0.281.32%N/A22.95%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
12.23
11.58
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/A
Relx Nv stock logo
RENX
Relx
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
11.50%
Relx Nv stock logo
RENX
Relx
1.37%

Insider Ownership

CompanyInsider Ownership
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.30%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
7.10%
Relx Nv stock logo
RENX
Relx
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
80106.42 million102.90 millionOptionable
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
3026.01 millionN/AN/A
Relx Nv stock logo
RENX
Relx
N/AN/AN/ANot Optionable

Recent News About These Companies

Rex win third straight game, beating Lafayette 9-7
Rex beat Paints
Riley, Diaz power Rex to victory over Chillicothe Paints
Rex’s Friday Morning Forecast - 6/27

New MarketBeat Followers Over Time

Media Sentiment Over Time

MaxCyte stock logo

MaxCyte NASDAQ:MXCT

$2.18 -0.02 (-0.91%)
As of 04:00 PM Eastern

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Palatin Technologies stock logo

Palatin Technologies NYSE:PTN

$0.09 -0.08 (-44.65%)
As of 05/7/2025

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Relx stock logo

Relx NYSE:RENX

RELX NV, through its interest in RELX Group plc, provides information and analytics for professional and business customers across industries worldwide. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment offers information and analytics to institutions and professionals. The Risk & Business Analytics segment provides solutions and decision tools that combine public and industry specific content with technology and analytics to evaluate and predict risk, as well as enhance operational efficiency. The Legal segment offers legal, regulatory, and business information and analytics. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier NV and changed its name to RELX NV in June 2015. RELX NV was incorporated in 1880 and is headquartered in Amsterdam, the Netherlands.